"Providence Regional Cancer System's Shelton Clinic is open for oncology and hematology consultations every Wednesday. This allows you to have regular visits with your oncologist, close to home."

During the past decade, Providence Regional Cancer System-Shelton conducted 129 clinical trials. In the 10-year time frame, 129 clinical trials started and 43 clinical trials were completed, i.e. on average, 33.3% percent of trials that started reached the finish line to date. In the past 5 years, 52 clinical trials started and 40 clinical trials were completed. i.e. 76.9% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Providence Regional Cancer System-Shelton" #1 sponsor was "National Cancer Institute (NCI)" with 67 trials, followed by "Alliance for Clinical Trials in Oncology" with 30 trials sponsored, "SWOG Cancer Research Network" with 27 trials sponsored, "ECOG-ACRIN Cancer Research Group" with 15 trials sponsored and "Gynecologic Oncology Group" with 15 trials sponsored. Other sponsors include 5 different institutions and companies that sponsored additional 10 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Providence Regional Cancer System-Shelton" #1 collaborator was "National Cancer Institute (NCI)" with 85 trials as a collaborator, "NRG Oncology" with 10 trials as a collaborator, "Canadian Cancer Trials Group" with 8 trials as a collaborator, "Genentech, Inc." with 3 trials as a collaborator and "Millennium Pharmaceuticals, Inc." with 2 trials as a collaborator. Other collaborators include 14 different institutions and companies that were collaborators in the rest 24 trials.

According to Clinical.Site data, the most researched conditions in "Providence Regional Cancer System-Shelton" are "Invasive Breast Carcinoma" (7 trials), "Recurrent Squamous Cell Lung Carcinoma" (7 trials), "Recurrent Ovarian Carcinoma" (6 trials), "Stage IV Lung Cancer AJCC v8" (6 trials) and "Stage IV Squamous Cell Lung Carcinoma AJCC v7" (6 trials). Many other conditions were trialed in "Providence Regional Cancer System-Shelton" in a lesser frequency.

Most popular intervention types in "Providence Regional Cancer System-Shelton" are "Drug" (123 trials), "Other" (86 trials), "Biological" (66 trials), "Procedure" (43 trials) and "Radiation" (13 trials). Other intervention types were less common.

The name of intervention was led by "Laboratory Biomarker Analysis" (40 trials), "Quality-of-Life Assessment" (38 trials), "Questionnaire Administration" (26 trials), "Biospecimen Collection" (25 trials) and "Computed Tomography" (25 trials). Other intervention names were less common.

The vast majority of trials in "Providence Regional Cancer System-Shelton" are 130 trials for "All" genders, 21 trials for "Female" genders and 1 trials for "Male" genders.

Currently, there are NaN active trials in "Providence Regional Cancer System-Shelton". undefined are not yet recruiting, 52 are recruiting, 72 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 19 completed trials in Providence Regional Cancer System-Shelton, 4 suspended trials, and 4 terminated clinical trials to date.

Out of the total trials that were conducted in Providence Regional Cancer System-Shelton, 5 "Phase 1" clinical trials were conducted, 81 "Phase 2" clinical trials and 73 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 3 trials that are defined as “Not Applicable".